ICLE 2022 | Targeting CD1c-expressing leukemia with engineered T-cells
CD1c-restricted T lymphocytes have been found to successfully target methyl-lysophosphatidic acids (mLPAs), which are presented by CD1c on certain leukemia cells. Michela Consonni, PhD, San Raffaele Scientific Institute, Millan, Italy, describes the development mLPA-specific T-cell receptors (TCRs) to target CD1c-expressing leukemia. A library of engineered TCRs were constructed and DN4.99 TCR-T cells were the most successful in targeting CD1c-expressing leukemia whilst avoiding healthy cells. Dr Consonni additionally discusses efforts to increase the avidity of the T-cell product and preventing graft versus host disease (GvHD) to further enhance the therapeutic potential. This interview took place at the International Conference on Lymphocyte Engineering (ICLE) 2022.
